Is Vitamin K Bone Health Meta-Analysis safe?

The current Migaku evidence database contains 2 reusable source documents for Vitamin K Bone Health Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Genetic variants in VKORC1 may influence bone mineral density (BMD) and osteoporosis risk. [Vesa ŞC (2026); evidence level 1] - The overall effect of VKORC1 risk alleles on osteopenia/osteoporosis was significant with a p = 0.041 (fixed effects OR = 1.16, 95% CI = 1.01-1.35). [Vesa ŞC (2026); evidence level 1] - The current body of evidence requires further studies to elucidate whether VKORC1 polymorphisms have a clinically meaningful role in bone health. [Vesa ŞC (2026); evidence level 1] - Background and Objectives: The vitamin K epoxide reductase complex subunit 1 (VKORC1) plays a central role in the vitamin K cycle, which is essential for γ-carboxylation of multiple bone-related proteins. [Vesa ŞC (2026); evidence level 1] - Accumulating evidence links this condition to impaired glucose [,,,,] and calcium metabolism [,], highlighting the need to better define VK’s roles within the endocrine regulatory pathways. [Matuszewski Wojciech (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.